Pharmacist-led screening for diabetic peripheral neuropathy using the Michigan Neuropathy Screening Instrument (MNSI) #ActAgainstAmputation @ALPSlimb

A great idea from our Jordanian colleagues.


Diabetic peripheral neuropathy (DPN) is highly prevalent among Jordanian patients, mostly are asymptomatic. Early recognition and appropriate management of neuropathy is important to improve symptoms, reduce sequelae, and improve quality of life. This study aims at exploring the role of pharmacists in the early recognition of DPN and providing quick screening for the presence of it among diabetic patients.

Material and Methods

A cross-sectional study was conducted at multi-pharmacy settings, in Irbid, Jordan. Twenty trained pharmacists who had bachelor’s degrees in pharmacy participated in data collection. A total of 400 patients with confirmed diagnosis of type 2 diabetes mellitus (DM) according to the World Health Organization diagnostic criteria were recruited. DPN was assessed using the translated Arabic version of Michigan Neuropathy Screening Instrument (MNSI) history version.


The mean MNSI questionnaire score for all participants was 4.40 ± 3.00. Mean age of the patients was 62.6 ± 10.7 years old and duration of diabetes was 8.25 ± 6.9. DN was present in 23.7% of the population. Diabetic patients with neuropathy were older than patients without neuropathy (P< 0.05) and had had diabetes longer (P< 0.05). Poor glycemic control, hypertension and gender, were significantly risk factors for DN (P< 0.05).


In addition to delivering medications, this study suggests that pharmacists can have a role in screening and counseling about diabetic peripheral neuropathy using a simple objective, and non-invasive tool and also can determine level of damage and risk.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Up ↑

Verified by MonsterInsights